C1-INH for Refractory Antibody Mediated Renal Allograft Rejection
| Status: | Enrolling by invitation |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 11/11/2017 |
| Start Date: | October 2016 |
| End Date: | October 2021 |
Use of C1-INH (Berinert) for Renal Allograft Salvage in Refractory Antibody Mediated Rejection
This is an open-label, single arm trial in which patient who have ongoing antibody mediated
rejection of a kidney transplant deemed refractory to maximal medical therapy are given the
complement inhibitor C1-INH (Berinert) in an effort to protect the graft from ongoing
antibody mediated injury. A maximum of 5 patients will be enrolled.
rejection of a kidney transplant deemed refractory to maximal medical therapy are given the
complement inhibitor C1-INH (Berinert) in an effort to protect the graft from ongoing
antibody mediated injury. A maximum of 5 patients will be enrolled.
Inclusion Criteria:
- Kidney transplant with acute antibody mediated rejection refractory to standard
therapy
Exclusion Criteria:
- Patients with known intolerance of or anaphylaxis to Berinert
We found this trial at
1
site
New York University School of Medicine NYU School of Medicine has a proud history that...
Click here to add this to my saved trials
